Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.36 |
| ▸ | RORC | P51449 | 9/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17981548 | 0.82 | RORC (0.39) | NOTUMRORC | |
| SCHEMBL15569786 | 0.81 | RORC (0.46) | DPP4ALDH1A1RORC | |
| SCHEMBL17323526 | 0.78 | CA12 (0.44) | HSD17B10NOTUMRORC | |
| 2,3,6-Trichlorobenzoic Acid SCHEMBL29365114 | 0.75 | DPP4 (0.62) | DPP4TSHRKDM4EALDH1A1HSD17B10 | |
| 2,3,6-Trichlorobenzoic Acid SCHEMBL117071 | 0.75 | DPP4 (0.62) | DPP4TSHRKDM4EALDH1A1HSD17B10 | |
| SCHEMBL15569264 | 0.75 | TAS1R3 (0.47) | ALDH1A1RORC | |
| SCHEMBL15570366 | 0.75 | TAS1R3 (0.47) | ALDH1A1RORC | |
| SCHEMBL15570286 | 0.74 | TAS1R3 (0.46) | RORC | |
| 2,3,6-Trichlorobenzoic Acid SCHEMBL10490012 | 0.73 | DPP4 (0.60) | DPP4TSHRKDM4EALDH1A1HSD17B10 | |
| SCHEMBL25080830 | 0.71 | LMNA (0.41) | P2RX7RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689369-B2 | Substituted indazole compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190276438-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276438-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | RORB, RORC, RORA | DPP4 3220/4885TSHR 944/4885KDM4E 3066/4885 |
| US-10689369-B2 | Substituted indazole compounds as RORgammaT inhibitors and uses thereof | RORB, RORC, RORA | DPP4 3220/4885TSHR 944/4885KDM4E 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.